Searched for
DYSLIPIDEMIA
For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Harvard liver specialist names top three best snacks to reverse fatty liver and the last one may surprise youFatty liver best snacks: Harvard liver specialist Dr Saurabh Sethi has named three powerful snacks to help reverse fatty liver and these in...
- Cholesterol test at age 18, Non-fasting measurement: Cardiologists Suggest New Guidelines on how to prevent heart attacksThe Cardiologist Society of India (CSI) now recommends lipid profiles starting at age 18, with non-fasting measurements as the new norm. Th...
- Apollo Hospitals launches AI-driven personalised preventive health profileApollo's 'ProHealth' program is backed by a predictive algorithm that captures one’s health status, predicts potential health risks and ind...
- Zydus Lifesciences launches drug for treating bad cholesterol"With Bemdac we are happy to introduce a first-in-India therapy to address the unmet medical need of people suffering from uncontrolled LDL...
- Zydus Cadila receives DCGI nod for NAFLD drug Saroglitazar Mg in IndiaNon-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of the liver, which starts with fat accumulation in the liver in patient...
- 'Ghar ka khana' for Chidambaram in Tihar JailSenior advocate Kapil Sibal, appearing for Chidambaram, told the court that the 74-year-old Congress leader was suffering from multiple ail...
- Zydus gets regulatory nod to market Lipaglyn in MexicoThe company has been granted marketing approval from the Mexican regulatory authority COFEPRIS to commercialise Lipaglyn in Mexico, Zydus s...
- Lupin gets USFDA nod for Pitavastatin tabletsThe company has received tentative approval from the United States Food and Drug Administration (USFDA) to market its Pitavastatin tablets.
- US FDA pulls up Cadila for misbranding drugThe company has been researching on the drug to treat fatty liver disease or non-alcoholic steatohepatitis apart from diabetic dyslipidemia.
- Cadila Healthcare misbranded Saroglitazar, says US FDAIn a December 21 letter to the company, the US FDA has said the “broad statements” made by the company as the “world’s first” is misleading...
- Europe approves Biocon's Rosuvastatin Calcium tabletsThe approval in the regulated markets marks an important milestone in Biocon's small molecules strategy of forward integration from APIs.
- Lupin launches generic Fenofibric Acid capsules in US marketLupin said its US arm has launched generic Fenofibric Acid capsules used for reducing cholesterol and fatty acids in the blood in the Ameri...
- Zydus to invest Rs 100 crore in Vadodara unit, expand hospital businessZydus Hospitals & Healthcare Research recently started its first hospital operations at Anand, better known as Amul's hometown.
- Zydus to launch first new chemical entity by desi companyCadila Healthcare on Wednesday said that its new chemical entity (NCE), Lipaglyn , has been approved by the Drug Controller General of Indi...
- Zydus Cadila to launch molecule for diabetesPharma major Cadila Healthcare may soon become one of a handful of Indian companies to launch an indigenously developed molecule.
- AstraZeneca India announces CRESTOR tablets launchAstraZeneca India announced the launch of CRESTOR® (rosuvastatin) 5, 10, 20 and 40 mg tablets. CRESTOR® is indicated for use in the treatme...
- Cadila files new drug application; share up nearly 1%Cadila Healthcare has filed an investigational new drug application for conducting clinical trials for molecular entity - ZYH7, to treat dy...
- Ranbaxy's cholesterol lowering drug acquired by PPDRanbaxy Laboratories on Tuesday said US-based contact research organisation PPD Inc has acquired exclusive worldwide license to develop, ma...
Load More
